ArticleCardiovascular and interventional radiology2025
Percutaneous Cryoablation of Central Liver Tumors with Thermal Protection of the Bile Duct.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the technical feasibility and outcome of cryoablation with simultaneous bile duct protection in patients with centrally located liver tumors (CLLT). MATERIAL AND
methodsThree patients (all male, 40-79 years) with CLLT located in close proximity to the right (n = 2) or left (n = 1) hepatic duct were included in this retrospective study. Prior to cryoablation, a nasobiliary tube was placed endoscopically in the respective bile duct. In two cases, additional temporary bile duct stent placement was performed. CT-guided cryoablation was realized with simultaneous bile duct perfusion using warm saline. Technical success, effectivity and complications were assessed.
resultsThree CLLT (hepatocellular carcinoma (HCC) n = 2; metastasis n = 1; tumor size 9-15 mm) were treated. Cryoablation was technically successful in all cases and treatment effectivity (A0 ablation) was 100%. Nasobiliary tubes were removed immediately after the ablation procedure, bile duct stents were removed -six to eight weeks after ablation. At the latest available follow-up for each patient (909, 343 and 32 days), no bile duct-related complications were observed. No local tumor recurrence was observed in the two patients who survived longer than three months.
conclusionAccording to our initial experience, percutaneous cryoablation of CLLT with simultaneous bile duct protection is technically feasible without an increased risk of biliary complications and local tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.